SOURCE-LINKED STUDY SUMMARY
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Abstract summarizedQuality not appraised
- What was studied
- Phase 2 randomized trial comparing daily semaglutide with placebo for fatty liver inflammation and scarring.
- Who / model studied
- 320 patients with biopsy-confirmed liver inflammation and fibrosis, treated for 72 weeks; main liver analyses included 230 with more advanced fibrosis.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- At the highest studied dose, inflammation resolved without worse scarring in 59% versus 17%. Scarring improved in 43% versus 33%, a difference that was not statistically clear. Weight fell 13% versus 1%. Digestive adverse events were more common. Tumors were reported in 15% across semaglutide groups versus 8% with placebo, including malignant tumors in 1% versus none.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2028395